• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Athenex Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    11/22/22 4:15:58 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNX alert in real time by email
    8-K
    false 0001300699 --12-31 0001300699 2022-11-22 2022-11-22

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 22, 2022

     

     

    ATHENEX, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38112   43-1985966

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1001 Main Street, Suite 600, Buffalo, New York   14203
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (716) 427-2950

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share   ATNX   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On November 22, 2022, at a special meeting of stockholders (the “Special Meeting”) of Athenex, Inc. (the “Company”), the stockholders of the Company approved the Second Amendment (the “Plan Amendment”) to the Company’s Amended and Restated 2017 Omnibus Incentive Plan (the “Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 12,500,000 shares and extend the term of the Plan until November 22, 2032.

    A detailed summary of the material features of the Plan Amendment is set forth in the Company’s definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on October 11, 2022 (the “Proxy Statement”). That summary is qualified in its entirety by reference to the text of the Plan, which is filed as Appendix D to the Proxy Statement, and the text of the Plan Amendment, which is filed as Exhibit 10.1 hereto, both of which are incorporated herein by reference.

     

    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    At the Special Meeting, the stockholders approved an amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (“Charter”) to increase the number of authorized shares of common stock, from 250,000,000 shares to 500,000,000 shares. Following this approval, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and it became effective at 4:00 p.m. Eastern Time on November 22, 2022.

    The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed hereto as Exhibit 3.1 and is incorporated herein by reference

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    The proposals set forth below, each as further described in the Proxy Statement, were submitted to the Company’s stockholders at the Special Meeting. The number of shares of common stock entitled to vote at the Special Meeting was 156,790,234. The number of shares of common stock present or represented by valid proxy at the Special Meeting was 103,464,115. The voting results for the proposals are as follows:

     

      1.

    The Company’s stockholders voted to approve an amendment to the Charter to effect an increase in the total number of authorized shares of the Company’s common stock from 250,000,000 shares to 500,000,000 shares. The number of shares that voted for, against, and abstained from voting for this proposal is summarized in the table below:

     

    FOR

     

    AGAINST

     

    ABSTAIN

    95,522,869   7,787,363   153,883

     

      2.

    The Company’s stockholders voted to approve an amendment to the Charter, at the discretion of the Board, to effect a reverse stock split of the issued and outstanding shares

     


      of common stock in a range of not less than one-for-five shares and not more than one-for-twenty shares, with a corresponding reduction in the total number of authorized shares of common stock in proportion to the reduction of the issued and outstanding shares. The number of shares that voted for, against, and abstained from voting for this proposal is summarized in the table below:

     

    FOR

     

    AGAINST

     

    ABSTAIN

    99,183,681   4,205,053   75,381

     

      3.

    The Company’s stockholders voted to approve the Plan Amendment. The number of shares that voted for, against, and abstained from voting for this proposal as well as the number of broker non-votes, is summarized in the table below:

     

    FOR

     

    AGAINST

     

    ABSTAIN

     

    BROKER NON-VOTES

    72,471,352   5,670,519   158,157   25,164,087

    Broker non-votes represent shares held by broker nominees for beneficial owners that were not voted because the broker nominee did not receive voting instructions from the beneficial owner and lacked discretionary authority to vote the shares on a non-routine proposal.

     

    Item 8.01

    Other Events.

    Also on November 22, 2022, the Company issued a press release announcing preliminary results of the Special Meeting. A copy of the press release is attached as Exhibit 99.1 to this report.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d)    Exhibits

     

    Exhibit
        No.    

      

    Description

      3.1    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Athenex, Inc., effective as of November 22, 2022
    10.1    Second Amendment to the Athenex, Inc. Amended and Restated 2017 Omnibus Incentive Plan
    99.1    Press release issued by the Company on November 22, 2022
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        ATHENEX, INC.
    Date: November 22, 2022    

    /s/ Joe Annoni

        Name:   Joe Annoni
        Title:   Chief Financial Officer
    Get the next $ATNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNX

    DatePrice TargetRatingAnalyst
    10/12/2021$8.00 → $5.00Outperform
    RBC Capital
    8/6/2021$9.00 → $8.00Outperform
    RBC Capital
    8/6/2021$5.00 → $4.00Market Perform
    SVB Leerink
    More analyst ratings

    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

    To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX) ("Athenex" or the "Company"), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceu

    5/14/23 11:15:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

    Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

    3/20/23 8:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex Announces a Reverse Stock Split

    BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on November 22, 2022, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's common stock, at

    2/14/23 8:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lau Johnson Yiu Nam

    4 - Athenex, Inc. (0001300699) (Issuer)

    5/8/23 4:36:36 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kwan Rudolf

    4 - Athenex, Inc. (0001300699) (Issuer)

    5/8/23 4:33:18 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cook Timothy Devere

    4 - Athenex, Inc. (0001300699) (Issuer)

    5/8/23 4:29:48 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    SEC Filings

    View All

    Athenex Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Leadership Update

    8-K - Athenex, Inc. (0001300699) (Filer)

    10/2/23 7:42:29 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex Inc. filed SEC Form 8-K: Leadership Update

    8-K - Athenex, Inc. (0001300699) (Filer)

    8/17/23 4:06:01 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Leadership Update

    8-K - Athenex, Inc. (0001300699) (Filer)

    7/18/23 9:03:58 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on Athenex with a new price target

    RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $5.00 from $8.00 previously

    10/12/21 6:58:34 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital reiterated coverage on Athenex with a new price target

    RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $8.00 from $9.00 previously

    8/6/21 9:52:27 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on Athenex with a new price target

    SVB Leerink reiterated coverage of Athenex with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously

    8/6/21 5:46:15 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    Leadership Updates

    Live Leadership Updates

    View All

    Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

    BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. "We are delighted to welcome Dr. Cohen to Athenex during this transformative period, as we strategically pivot to focus on advancing first-in-class

    6/8/22 8:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex Announces Appointment of Chief Financial Officer

    BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. "The Board of Directors joins me in welcoming Joe to his new position as CFO," said Johnson Lau, Chief

    2/22/22 8:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Athenex Inc. (Amendment)

    SC 13D/A - Athenex, Inc. (0001300699) (Subject)

    2/14/23 4:10:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Athenex Inc.

    SC 13D - Athenex, Inc. (0001300699) (Subject)

    2/2/23 5:01:53 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Athenex Inc. (Amendment)

    SC 13G/A - Athenex, Inc. (0001300699) (Subject)

    2/14/22 3:50:00 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    Financials

    Live finance-specific insights

    View All

    Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

    Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

    3/20/23 8:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

    BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: 1-844-826-3033 International: 1-412-317-5185 Pass

    10/24/22 8:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athenex Provides Second Quarter 2022 Financial Results and Business Update

    Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respectivelyMaintains full-year 2022 product revenue guidance range of 20-25% growth year-over-year Management to host conference call and webcast today at 8:00 a.m. EDT BUFFALO, N.Y.

    7/28/22 7:00:00 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care